Is Xeljanz approved for alopecia areata?
No, Xeljanz (tofacitinib) is not FDA-approved for alopecia areata. The agency approved it in 2012 for rheumatoid arthritis, with later expansions to psoriatic arthritis, ulcerative colitis, and ankylosing spondylitis.[1]
How is Xeljanz used off-label for alopecia areata?
Physicians prescribe Xeljanz off-label for severe alopecia areata, an autoimmune condition causing patchy hair loss. Studies show it promotes hair regrowth by blocking JAK enzymes that drive immune attacks on hair follicles. A 2016 phase 2 trial reported 60-70% of patients with significant regrowth after 3-6 months at 5 mg twice daily.[2] Real-world use targets patients unresponsive to steroids or other topicals.
What do recent clinical trials show?
Pfizer ran phase 3 trials (ALLEGRO) testing oral ritlecitinib, a related JAK inhibitor, which succeeded in 2022—leading to FDA approval of Litfulo for severe alopecia areata in ages 12+.[3] Tofacitinib trials remain smaller; a 2023 meta-analysis of 17 studies found 57% response rates but noted relapse after stopping.[4] No large phase 3 data exists for Xeljanz itself.
Why consider JAK inhibitors like Xeljanz for hair loss?
Alopecia areata involves JAK-STAT pathway overactivity. Xeljanz inhibits JAK1/3, reducing inflammation faster than biologics like dupilumab. It's oral, unlike injectables, appealing for widespread cases.
What are the main risks and side effects?
Common issues include infections (shingles, upper respiratory), headaches, diarrhea, and elevated cholesterol. Black box warnings cover serious infections, malignancies, clots, and GI tears—higher risk in alopecia patients on long-term use.[1] Monitoring requires blood tests; not for mild cases due to risks outweighing benefits.
How does it compare to Litfulo or other treatments?
Litfulo (ritlecitinib) is the first approved oral JAK for alopecia areata, targeting JAK3 more selectively with fewer broad immune effects than Xeljanz. Olumiant (baricitinib) has tentative approval signals. Topicals like JAK inhibitor creams (e.g., deuruxolitinib, approved 2024) suit milder cases. Xeljanz costs $5,000+/month without insurance; generics unavailable until patents expire around 2025-2030.[5]
When might Xeljanz gain approval or alternatives emerge?
No active approval push for alopecia areata; focus shifted to selective JAKs. Biosimilars for Xeljanz could enter post-2025, potentially lowering off-label costs. Consult a dermatologist for personalized risks.
Sources
[1] FDA Label for Xeljanz
[2] NEJM: Phase 2 Tofacitinib Trial
[3] FDA Approval: Litfulo
[4] JAMA Dermatology Meta-Analysis
[5] DrugPatentWatch: Xeljanz Patents